Cantor Fitzgerald reiterates HCA Healthcare stock rating at Overweight

Investing.com - Cantor Fitzgerald reiterated an Overweight rating on HCA Healthcare Inc (NYSE:HCA) shares with a price target of $588.00. The hospital operator, with a market capitalization of $111.5 billion, currently trades at a P/E ratio of 17.9. According to InvestingPro analysis, HCA appears slightly undervalued at current levels, with the platform identifying the stock as a prominent player in the Healthcare Providers & Services industry. The company reports earnings in nine days on April 24.

The firm’s first-quarter 2026 healthcare information technology survey covered 7% of U.S. inpatient beds. Healthcare providers indicated continued interest in healthcare IT investment but are unlikely to materially accelerate purchases in 2026.

Survey respondents’ outlook on 2026 shifted lower, with 30% less optimistic in the first quarter of 2026 compared to 16% in the fourth quarter of 2025. Providers face the expiration of enhanced Affordable Care Act premium tax credits and other challenges in 2026. Despite sector headwinds, InvestingPro Tips highlight that six analysts have revised their earnings upwards for HCA’s upcoming period, with analyst price targets ranging from $425 to $635. Subscribers can access 8 additional ProTips for deeper insights.

Cantor Fitzgerald characterized the survey results as a soft readthrough to the healthcare IT sector. The survey findings suggest providers remain cautious about increasing their technology spending despite ongoing interest in the investment cycle.

HCA Healthcare operates hospitals and healthcare facilities across the United States.

In other recent news, HCA Healthcare has been the focus of several analyst updates. Cantor Fitzgerald reiterated an Overweight rating for HCA Healthcare with a price target of $588.00, highlighting the company’s strong performance in first-quarter 2026 data, particularly in inpatient psychiatric and physician bonuses. Additionally, survey results showed a positive trend, with 70% of respondents viewing 2026 favorably compared to 2025. Cantor Fitzgerald also noted that HCA’s 2026 EBITDA guidance of 2.7% year-over-year growth exceeded investor expectations, which anticipated flat growth.

Meanwhile, TD Cowen raised its price target for HCA Healthcare from $529 to $561, maintaining a Buy rating. This increase reflects the firm’s confidence in HCA’s ability to execute its 2026 guidance, following the company’s presentation at the TD Cowen healthcare conference. In contrast, Cantor Fitzgerald maintained a Neutral rating for Acadia Healthcare, with a $20.00 price target, noting that 70% of survey respondents expect 2026 days per patient to exceed 2025 levels. These updates reflect the latest developments and assessments from analysts on HCA Healthcare and Acadia Healthcare.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.